journal
Journals Journal of the National Compre...

Journal of the National Comprehensive Cancer Network : JNCCN

https://read.qxmd.com/read/36828029/hypophysitis-and-secondary-adrenal-insufficiency-from-immune-checkpoint-inhibitors-diagnostic-challenges-and-link-with-survival
#1
JOURNAL ARTICLE
Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, Anupam Kotwal
BACKGROUND: Hypophysitis is a serious adverse event stemming from immune checkpoint inhibitor (ICI) therapy for malignancy. This study aimed to characterize ICI-induced hypophysitis, identify diagnostic challenges, and evaluate an association with survival in a large cancer cohort. METHODS: We performed a retrospective cohort study of adult patients with cancer who received ICIs between December 1, 2012, and December 31, 2019. We identified 839 patients who received CTLA-4, PD-1, or PD-L1 inhibitors or a combination thereof who were followed for a median of 19...
February 24, 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36812939/a-real-world-comparison-of-regorafenib-and-trifluridine-tipiracil-in-refractory-metastatic-colorectal-cancer-in-the-united-states
#2
JOURNAL ARTICLE
Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, Ignacio Garrido-Laguna
BACKGROUND: Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the United States for treatment of refractory metastatic colorectal cancer (mCRC). FDA approvals of these agents were based on modest improvements in overall survival (OS) compared with best supportive care + placebo in the RECOURSE and CORRECT trials, respectively. This study compared real-world clinical outcomes with the use of these agents. METHODS: A nationwide deidentified electronic health record-derived database was reviewed for patients diagnosed with mCRC between 2015 and 2020...
February 22, 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36812938/posttraumatic-stress-symptoms-in-patients-with-cancer-during-the-covid-19-pandemic-a-one-year-longitudinal-study
#3
JOURNAL ARTICLE
Etienne Bastien, Sophie Lefèvre-Arbogast, Justine Lequesne, François Gernier, François Cherifi, Olivier Rigal, Lydia Guittet, Jean-Michel Grellard, Giulia Binarelli, Marie Lange, Marie Fernette, Laure Tron, Adeline Morel, Doriane Richard, Bénédicte Griffon, Alexandra Leconte, Florian Quilan, Louis-Ferdinand Pépin, Fabrice Jardin, Marianne Leheurteur, Audrey Faveyrial, Bénédicte Clarisse, Florence Joly
BACKGROUND: Patients with cancer may be particularly vulnerable to psychological consequences of the COVID-19 pandemic. We studied the prevalence and evolution of posttraumatic stress symptoms (PTSS) in patients with cancer during the pandemic waves, and we investigated factors associated with high symptoms. METHODS: COVIPACT is a 1-year longitudinal prospective study of French patients with solid/hematologic malignancies receiving treatment during the first nationwide lockdown...
February 22, 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791749/small-cell-lung-cancer-in-light-never-smokers-a-role-for-molecular-testing
#4
JOURNAL ARTICLE
Gordon Taylor Moffat, Tao Wang, Andrew G Robinson
This report describes the management of small cell lung cancer (SCLC) transformation in a patient with untreated ALK-mutated advanced disease and a minimal smoking history, and a separate case of a de novo SCLC in a lifelong nonsmoker found to have a potentially targetable ERBB2 alteration. In the first case, chemotherapy followed by a targeted inhibitor was chosen due to the presence of the ALK rearrangement, as well as a somewhat discordant response to induction chemotherapy, suggesting possible progression of the ALK inhibitor-sensitive component...
February 15, 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36758579/unusual-adverse-events-in-a-patient-with-braf-mutated-non-small-cell-lung-cancer-treated-with-braf-mek-inhibition
#5
JOURNAL ARTICLE
Rohan Maniar, Stephanie M Gallitano, Sameera Husain, Golnaz Moazami, Michael J Weiss, Catherine A Shu
BRAF/MEK inhibition remains standard of care for treatment of BRAF-mutated non-small cell lung cancer (NSCLC). Although common adverse events (AEs) have been reported through clinical trials and ongoing clinical practice, only a handful of reports have detailed unusual adverse events associated with these medications. This report presents a patient with BRAF-mutated NSCLC treated with dabrafenib and trametinib who experienced 2 unusual AEs-Sweet syndrome and MEK-associated retinopathy-that responded to steroid treatment...
February 9, 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898367/smoking-cessation-version-3-2022-nccn-clinical-practice-guidelines-in-oncology
#6
JOURNAL ARTICLE
Peter G Shields, Laura Bierut, Douglas Arenberg, David Balis, Paul M Cinciripini, James Davis, Donna Edmondson, Joy Feliciano, Brian Hitsman, Karen S Hudmon, Michael T Jaklitsch, Frank T Leone, Pamela Ling, Danielle E McCarthy, Michael K Ong, Elyse R Park, Judith Prochaska, Argelia J Sandoval, Christine E Sheffer, Sharon Spencer, Jamie L Studts, Tawee Tanvetyanon, Hilary A Tindle, Elisa Tong, Matthew Triplette, James Urbanic, Gregory Videtic, David Warner, C Will Whitlock, Beth McCullough, Susan Darlow
Although the harmful effects of smoking after a cancer diagnosis have been clearly demonstrated, many patients continue to smoke cigarettes during treatment and beyond. The NCCN Guidelines for Smoking Cessation emphasize the importance of smoking cessation in all patients with cancer and seek to establish evidence-based recommendations tailored to the unique needs and concerns of patients with cancer. The recommendations contained herein describe interventions for cessation of all combustible tobacco products (eg, cigarettes, cigars, hookah), including smokeless tobacco products...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898366/primary-mediastinal-b-cell-lymphoma-in-children-and-young-adults
#7
REVIEW
Christopher J Forlenza, Amy Chadburn, Lisa Giulino-Roth
Primary mediastinal B-cell lymphoma (PMBCL) is a rare but aggressive mature B-cell lymphoma that arises from thymic B cells and most commonly affects adolescents and young adults. PMBCL is now recognized by the WHO as a distinct entity from diffuse large B-cell lymphoma (DLBCL), not otherwise specified, with a unique clinical presentation and distinct morphologic features and molecular alterations. Similar to classic Hodgkin lymphoma, PMBCL tumors are characterized by alterations in the nuclear factor-κB and JAK/STAT pathways...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898365/evaluating-germline-testing-panels-in-southern-african-males-with-advanced-prostate-cancer
#8
JOURNAL ARTICLE
Kazzem Gheybi, Jue Jiang, Shingai B A Mutambirwa, Pamela X Y Soh, Zsofia Kote-Jarai, Weerachai Jaratlerdsiri, Rosalind A Eeles, M S Riana Bornman, Vanessa M Hayes
BACKGROUND: Germline testing for prostate cancer is on the increase, with clinical implications for risk assessment, treatment, and management. Regardless of family history, NCCN recommends germline testing for patients with metastatic, regional, very-high-risk localized, and high-risk localized prostate cancer. Although African ancestry is a significant risk factor for aggressive prostate cancer, due to a lack of available data no testing criteria have been established for ethnic minorities...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898364/dying-in-the-queue-and-where-is-my-nurse
#9
JOURNAL ARTICLE
Margaret Tempero
No abstract text is available yet for this article.
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898363/feasibility-and-effectiveness-of-self-management-education-and-coaching-on-patient-activation-for-managing-cancer-treatment-toxicities
#10
JOURNAL ARTICLE
Doris Howell, Gregory R Pond, Denise Bryant-Lukosius, Melanie Powis, Patrick T McGowan, Tutsirai Makuwaza, Vishal Kukreti, Sara Rask, Saidah Hack, Monika K Krzyzanowska
BACKGROUND: Poorly managed cancer treatment toxicities negatively impact quality of life, but little research has examined patient activation in self-management (SM) early in cancer treatment. METHODS: We undertook a pilot randomized trial to evaluate the feasibility, acceptability, and preliminary effectiveness of the SMARTCare (Self-Management and Activation to Reduce Treatment Toxicities) intervention. This intervention included an online SM education program (I-Can Manage) plus 5 sessions of telephone cancer coaching in patients initiating systemic therapy for lymphoma or colorectal or lung cancer at 3 centers in Ontario, Canada, relative to a usual care control group...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898362/nccn-guidelines%C3%A2-insights-prostate-cancer-early-detection-version-1-2023
#11
JOURNAL ARTICLE
Kelvin A Moses, Preston C Sprenkle, Clinton Bahler, Geoffrey Box, Sigrid V Carlsson, William J Catalona, Douglas M Dahl, Marc Dall'Era, John W Davis, Bettina F Drake, Jonathan I Epstein, Ruth B Etzioni, Thomas A Farrington, Isla P Garraway, David Jarrard, Eric Kauffman, Deborah Kaye, Adam S Kibel, Chad A LaGrange, Paul Maroni, Lee Ponsky, Brian Reys, Simpa S Salami, Alejandro Sanchez, Tyler M Seibert, Terrence M Shaneyfelt, Marc C Smaldone, Geoffrey Sonn, Mark D Tyson, Neha Vapiwala, Robert Wake, Samuel Washington, Alice Yu, Bertram Yuh, Ryan A Berardi, Deborah A Freedman-Cass
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898361/external-validation-of-risk-factors-for-unplanned-hospitalization-in-older-adults-with-advanced-cancer-receiving-chemotherapy
#12
JOURNAL ARTICLE
Mostafa R Mohamed, Kah Poh Loh, Supriya G Mohile, Michael Sohn, Tracy Webb, Megan Wells, Sule Yilmaz, Rachael Tylock, Eva Culakova, Allison Magnuson, Can-Lan Sun, James Bearden, Judith O Hopkins, Bryan A Faller, Heidi D Klepin
BACKGROUND: Older adults (age ≥65 years) receiving chemotherapy are at risk for hospitalization. Predictors of unplanned hospitalization among older adults receiving chemotherapy for cancer were recently published using data from a study conducted by the Cancer and Aging Research Group (CARG). Our study aimed to externally validate these predictors in an independent cohort including older adults with advanced cancer receiving chemotherapy. METHODS: This validation cohort included patients (n=369) from the GAP70+ trial usual care arm...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36898360/visa-constraints-and-career-choices-for-oncologists
#13
JOURNAL ARTICLE
Farah Mazahreh, Ahmad A Al-Hader, Samer Al Hadidi
No abstract text is available yet for this article.
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791763/patient-reported-outcome-measures-in-chemotherapy-induced-peripheral-neurotoxicity-defining-minimal-and-clinically-important-changes
#14
JOURNAL ARTICLE
Tiffany Li, Hannah C Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G Horvath, Peter Grimison, Michael Friedlander, Matthew C Kiernan, Madeleine T King, Claudia Rutherford, David Goldstein, Susanna B Park
BACKGROUND: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common complication of cancer treatment that produces functional disability. Increasingly, patient-reported outcome measures (PROMs) are used to assess CIPN, providing a broader symptom perspective than clinician-graded scales. Understanding when a reported change in CIPN symptoms meets the threshold for clinical significance is challenging. This study aimed to provide interpretation guidelines for validated CIPN PROMs, and thereby enable estimation of thresholds to identify clinically relevant symptoms...
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791762/nccn-guidelines%C3%A2-insights-hematopoietic-cell-transplantation-version-3-2022
#15
JOURNAL ARTICLE
Ayman Saad, Alison Loren, Javier Bolaños-Meade, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Hany Elmariah, Sherif Farag, Krishna Gundabolu, Jonathan Gutman, Vincent Ho, Rasmus Hoeg, Mitchell Horwitz, Joe Hsu, Adetola Kassim, Mohamed Kharfan Dabaja, John Magenau, Thomas Martin, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Cameron Ninos, Caspian Oliai, Seema Patel, Brion Randolph, Mark Schroeder, Dimitrios Tzachanis, Asya Nina Varshavsky-Yanovsky, Madhuri Vusirikala, Frankie Algieri, Lenora A Pluchino
The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT-to enable the patient and clinician to assess management options in the context of an individual patient's condition...
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791761/your-words-mean-something
#16
JOURNAL ARTICLE
Margaret Tempero
No abstract text is available yet for this article.
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791760/patient-reported-symptom-complexity-and-acute-care-utilization-among-patients-with-cancer-a-population-based-study-using-a-novel-symptom-complexity-algorithm-and-observational-data
#17
JOURNAL ARTICLE
Linda Watson, Siwei Qi, Claire Link, Andrea DeIure, Arfan Afzal, Lisa Barbera
BACKGROUND: Patients with cancer in Canada are often effectively managed in ambulatory settings; however, patients with unmanaged or complex symptoms may turn to the emergency department (ED) for additional support. These unplanned visits can be costly to the healthcare system and distressing for patients. This study used a novel patient-reported outcomes (PROs)-derived symptom complexity algorithm to understand characteristics of patients who use acute care, which may help clinicians identify patients who would benefit from additional support...
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791759/current-evidence-based-systemic-therapy-for-advanced-and-recurrent-endometrial-cancer
#18
REVIEW
Sushmita Gordhandas, William A Zammarrelli, Eric V Rios-Doria, Angela K Green, Vicky Makker
Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide increasing incidence and disease-associated mortality. Although most patients with EC are diagnosed with early-stage disease, systemic treatment options for patients with advanced or recurrent EC have historically been limited. EC-focused clinical trials and the ensuing therapeutic landscape have expanded since The Cancer Genome Atlas (TCGA) identified 4 distinct EC subgroups associated with differential survival. This endeavor revolutionized our understanding of the genomic characterization of EC as well as molecular drivers of this heterogeneous malignancy, leading to precision oncology approaches to therapeutics and advancement in treatment options...
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791758/understanding-disparities-a-case-illustrative-of-the-struggles-facing-transgender-and-gender-diverse-patients-with-cancer
#19
JOURNAL ARTICLE
Elizabeth J Cathcart-Rake, Juliana M Kling, Evelyn F Carroll, Caroline Davidge-Pitts, Jennifer Le-Rademacher, Jennifer L Ridgeway, Cesar A Gonzalez, Aminah Jatoi
No abstract text is available yet for this article.
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36791757/advancing-more-equitable-care-through-the-development-of-a-health-equity-report-card
#20
JOURNAL ARTICLE
Alyssa A Schatz, Shonta Chambers, Gretchen C Wartman, Lisa A Lacasse, Crystal S Denlinger, Kristen M Hobbs, Lindsey Bandini, Robert W Carlson, Robert A Winn
The root causes of racial disparities in access to optimal cancer care and related cancer outcomes are complex, multifactorial, and not rooted in biology. Contributing factors to racial disparities in care delivery include implicit and explicit bias, lack of representation of people of color in the oncology care and research workforce, and homogenous research participants that are not representative of the larger community. Systemic and structural barriers include policies leading to lack of insurance and underinsurance, costs of cancer treatment and associated ancillary costs of care, disparate access to clinical trials, and social determinants of health, including exposure to environmental hazards, access to housing, childcare, and economic injustices...
February 2023: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.